Mirum Pharmaceuticals, Inc. - 8-K Filing

Mirum Pharmaceuticals announces positive Cohort 2 PROGRESS study results for ATEBRIOZ in pediatric FOP patients aged 6 to <12 years. (Items: 8.01 Other Events)

SEC EDGAR ·

Tickers: $MIRM

Read the full article at SEC EDGAR

More Regulatory news